Undecimal Bio Raises $18 Million for RNA Drug Revolution
Translated & summarized from TheMarker by baba
Israeli biotech startup Undecimal Bio has raised $18 million in its initial seed funding round, led by UK firms IQ Capital and 4Bio Capital. The company, spun out from Eleven Therapeutics, aims to expand the use of RNA drugs and develop its own treatments. This funding will support its platform development and drug discovery efforts.
The story in 4 lines · by baba
- Undecimal Bio secured $18 million in seed funding led by IQ Capital and 4Bio Capital.
- The biotech startup is focused on expanding the use of RNA-based drugs.
- Undecimal Bio was spun out from the parent company Eleven Therapeutics.
- The company plans to develop its own RNA-based therapeutic drugs.
Israeli biotech startup Undecimal Bio has announced a successful seed funding round, raising $18 million. The funding was led by UK-based venture capital firms IQ Capital and 4Bio Capital.
Undecimal Bio is one of two new startups spun out from the biotech company Ilan Erlich and Ilan, named Eleven Therapeutics. The company's focus is on developing a platform designed to broaden the application and diversity of RNA-based drugs, and it also plans to develop its own therapeutic treatments.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
